Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04 2024 - 3:30PM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that on April 1,
2024, an authorized sub-committee of the Board of Directors of
Mersana granted an inducement award, consisting of a restricted
stock unit (RSU) award to acquire 35,100 shares of its common
stock, to one new employee whose employment commenced in March
2024. The award was granted as an inducement material to the new
employee entering employment with Mersana in accordance with Nasdaq
Listing Rule 5635(c)(4).
The RSU award will vest in equal annual installments on the
first four anniversaries of February 15, 2024, subject to the
employee’s continued service with Mersana on each such vesting
date. The RSU award is subject to the terms and conditions of
Mersana’s 2022 Inducement Stock Incentive Plan and the terms and
conditions of an RSU agreement covering the grant.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company focused on the
development of novel antibody-drug conjugates (ADCs) and driven by
the knowledge that patients are waiting for new treatment options.
The company has developed proprietary cytotoxic (Dolasynthen) and
immunostimulatory (Immunosynthen) ADC platforms that are generating
a pipeline of wholly-owned and partnered product candidates with
the potential to treat a range of cancers. Its pipeline includes
XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an
Immunosynthen ADC targeting a novel epitope of human epidermal
growth factor receptor 2 (HER2). Mersana routinely posts
information that may be useful to investors on the “Investors &
Media” section of its website at www.mersana.com.
Contact:Jason
Fredette617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2024 to May 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From May 2023 to May 2024